In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the FDA revisits its decision to remove it.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...

New research estimates that expanded access to Ozempic and similar drugs could lead to 42,000 deaths prevented annually.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...